Novo Nordisk on Thursday said it will invest more than 16 billion Danish kroner, or about $2.3 billion, to expand a drug production site in Chartres, France, as it works to keep up with demand for medicines like its sought-after GLP-1 drugs for diabetes and obesity.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,